Mar 14 |
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
|
Mar 6 |
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
|
Mar 6 |
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
|
Feb 21 |
Innate Pharma Announces Its Participation to Upcoming Investor Conference
|
Jan 12 |
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
|
Jan 11 |
Innate Pharma: Worth A Deeper Look
|
Jan 4 |
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
|
Jan 4 |
FDA lifts partial clinical hold on Innate Pharma's lacutamab clinical program; leadership change
|
Jan 4 |
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
|
Jan 4 |
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
|